Newsletter

445680 - Curiox Biosystems Co., Ltd.

445680 Summary
Medical Devices
Stock Price & Overview
₩47,650 -750 (-1.55%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩47,650  ≈ US$34  ·  Market cap ₩0.8tn (≈ $586m)

445680 Quarterly Results

Quarter ₩bnRevenueYoYOperating incomeMarginYoYNet incomeEPS
2026 Q21.2+18.1%-4.5-379.1%—-4.8₩-281
2026 Q11.3+43.7%-3.3-245.5%—-2.6₩-153
2025 Q41.8+93.5%-2.7-143.4%—-2.3₩-132
2025 Q31.4+45.5%-2.7-193.6%—-3.0₩-176
2025 Q21.0-8.9%-4.0-397.5%—-18.3₩-1,061
2025 Q10.9-41.9%-3.0-328.0%—-3.6₩-210
2024 Q41.0—-3.6-379.6%—1.7₩97
2024 Q31.0—-3.3-342.6%—-4.0₩-233
Three-month figures from DART consolidated statements. Q4 is the annual figure less the nine-month cumulative. EPS is net income over today's share count, so buybacks and issuance move earlier quarters. YoY compares with the same quarter a year earlier and is blank when that quarter was a loss.

445680 Annual Results

Full statements »
Fiscal year ₩bnRevenueYoYOperating incomeMarginYoYNet incomeEPS
FY20255.2+12.3%-12.3-239.0%—-27.2₩-1,579
FY20244.6-32.4%-13.4-291.6%—-8.1₩-470
FY20236.8-6.2%-10.6-155.5%—-10.0₩-583
FY20227.2+31.0%-11.4-157.8%—-11.5₩-668
FY20215.5—-8.3-151.0%—-14.5₩-844

445680 Next Report

The latest quarter on file is 2026 Q2. The next one, the Q3 2026 report covering the period to Sep 30, 2026, is due on DART by Nov 14, 2026 — Korean issuers must file quarterly and half-year reports within 45 days of period end and the annual report within 90 days.

Large issuers usually publish preliminary consolidated figures (잠정실적, a fair-disclosure filing with revenue and operating profit only) in the first weeks after the period ends, ahead of the full report. kstock does not know a company's chosen release date; when the preliminary filing arrives it appears under Filings and on this page.

445680 Earnings Filings

All filings »
DART

Half-Year Report

Periodic08/14/26title translated
DART

Preliminary Consolidated Results (Fair Disclosure)

Earnings08/06/26title translated
DART

Quarterly Report

Periodic05/15/26title translated

How Korean earnings differ from US earnings

  • No quarterly guidance culture. Most KRX companies give no EPS or revenue guidance; the preliminary filing is the first number the market sees, and there is no consensus beat/miss ritual built around it.
  • Preliminary first, then the report. The 잠정실적 filing carries revenue and operating profit; net income and the balance sheet come with the full report weeks later.
  • Consolidated is the headline. Korean companies report consolidated (K-IFRS) and separate (parent-only) figures; kstock uses consolidated unless the page says otherwise.
  • Fiscal years end in December for almost every listed company, so Q4 is derived: the annual figure less the nine-month cumulative.

Similar to 445680

SymbolLast Price
096530Seegene, Inc.₩31,900
+1.1%
491000Livs Med, Inc.₩34,500
+3.6%
041830In Body Co., Ltd.₩61,100
+2.5%
458870Seers Co., Ltd.₩21,350
+3.1%
137310SD Biosensor₩6,160
-0.3%
377740Bio Note, Inc.₩4,790
-0.2%
340570T & L Co., Ltd.₩29,650
+1.2%
099190i-SENS, Inc.₩16,470
+0.0%
336570WON Tech Co., Ltd.₩4,905
+0.9%
174900Ab Clon, Inc.₩21,600
+5.9%
Compare all 13 in Medical Devices

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.